Product Datasheet  
Retinoic Acid Receptor alpha Antibody  
Catalog Number: 49093  
Technical:tech@swbio.com  
Information:info@swbio.com  
Description  
  • host_species：  
  • Amount：  
  • 100μgμg
  • Swiss-Prot No.：  
  • Swiss-Prot#:P10276
  • Form of Antibody：  
  • 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.
  • Storage：  
  • Store at -20˚C
  • Immunogen：  
  • recombinant protein
  • reactivity：  
  • Hu, Ms
  • appl_detail：  

  • WB: 1:1,000



    FC: 1:50-1:100

  • other_names：  
  • NR1B1 antibody
    Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein antibody
    Nuclear receptor subfamily 1 group B member 1 antibody
    Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form antibod
  • Purification：  
  • ProA affinity purified
  • Specificity：  
  • Applications：  
  • WB, FC
  • Background：  

  • Retinoids (RA) are metabolites of vitamin A (retinol) that are important signaling molecules during vertebrate development and tissue differentiation. RAs activate the retinoic acid receptor (RAR) and retinoid X receptor (RXR) nuclear transcription factor families. Most retinoid forms activate RAR family members, whereas RXR family members are activated by 9-cis-RA only. RAR family members, which include RARα, RARβ and RARγ, have a high affinity for all transretinoic acids and belong to the same class of nuclear transcription factors as thyroid hormone receptors, vitamin D3 receptor and ecdysone receptor. RAR isoforms are expressed in distinct patterns throughout development and in the mature organism. The human RARα gene maps to chromosome 17 and is implicated in the chromosomal translocation associated with acute promyelocytic leukemia (APL-M3). Specifically, the RARα gene is fused with the promyelocytic leukemia (PML) gene, which encodes the fusion protein PML/RARα. The PML/RARα fusion protein inhibits PML-dependent apoptotic pathways and halts myeloid differentiation at the promyelocytic stage.




 
© Signalway Biotechnology All Rights Reserved.